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ABSTRACT
Subclinical hypothyroidism (SHT) is a biochemical diagnosis, defined as an elevated Thyroid Stimulating 
Hormone (TSH) with normal free thyroxine (FT4). It affects 4-10% of the adult population and is 
more prevalent in elderly women. Its commonest cause is autoimmune thyroiditis, detected by anti-
thyroid peroxidase antibody (TPO-Ab).  About 2-5% of SHT patients progress to overt hypothyroidism 
annually. The SHT prevalence among depressed patients ranges between 3% and 17%. This study aimed 
to determine the prevalence of SHT and TPO-Ab positivity among patients diagnosed with depressive 
disorders. It was a cross-sectional study carried out in the Universiti Kebangsaan Malaysia Medical 
Centre over a 12 months period. Serum TSH, FT4 and TPO-Ab were measured. Results showed that 
82% of depressed patients were euthyroid, 4% had SHT, 11% had subclinical hyperthyroidism and 2% 
had discordant thyroid function. TPO-Ab positivity among the subjects was 7%, one of whom had SHT. 
In conclusion, the prevalence of SHT and TPO-Ab positivity in the study population, at 4% and 7%, 
respectively, were comparable to previous findings.
Key words: Subclinical hypothyroid, prevalence, depressed patients, anti-thyroid peroxidase 
antibody.
INTRODUCTION
SHT is a biochemical diagnosis, characterized by an elevated serum TSH concentration above the statistically defined 
upper limit of the reference range when serum FT4 concentration is within its reference range.1 Patients are usually 
asymptomatic but mild non-specific symptoms may sometimes be present.1 The magnitude of TSH divides SHT into 
mild or severe.2 Biochemically, SHT entity is explained by the exquisitely sensitive inverse log-linear relationship of 
hypothalamus-pituitary-thyroid (HPA) axis, with each individual having a genetically-determined HPA axis set-point.3 
Diagnosis of SHT is made only after persistent TSH elevation on repeat sample and exclusion of transient increase or 
laboratory error.1,4
Much of the data on the prevalence of SHT comes from two large population-based studies, namely the Whickham 
Survey and the National Health and Nutritional Examination Survey (NHANES) III.1 Its prevalence is between 4 and 
10% of adult population samples.5,6 The prevalence increased with age in women (up to 20% over 60 years)2 and the 
most common cause of SHT is Hashimoto’s (autoimmune) thyroiditis.1 Not all patients with SHT progress to overt 
hypothyroidism.1 The rate of progression is proportional to the baseline serum TSH concentration and is higher in 
patients with anti-thyroid antibodies.4
Depression is the most common mood disorder, estimated to affect 350 million worldwide.7 The link between 
thyroid dysfunction and depression has long been recognized.8 Dysfunctional hypothalamus-pituitary-thyroid (HPT) 
axis have been documented in patients with depression9,10 and such abnormalities were often associated with elevated 
anti-thyroid antibody.10,11 It has also been suggested that the outcome of treatment and the course of depression, may 
be related to thyroid status, particularly thyroid autoimmunity.11,12
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The prevalence of depression was higher in patients with SHT than in the general population.13 Recent studies 
relating SHT and depression have shown varied findings.14-16 Nevertheless, the American Association of Clinical 
Endocrinologists (AACE) guidelines stated that the diagnosis of subclinical or clinical hypothyroidism must be 
considered in every patient with depression.17
As depressive disorders are one of the most common psychiatric illnesses in Malaysia, with a prevalence of 
approximately 5-6%18 and the possible link between depression and SHT, this study aimed to determine the prevalence 
of SHT and TPO-Ab positivity among patients with depressive disorders in Universiti Kebangsaan Malaysia Medical 
Centre (UKMMC).
MATERIAL AND METHODS
This was a cross-sectional study carried out in the Universiti Kebangsaan Malaysia Medical Centre (UKMMC). 
Subject recruitment was done by convenient sampling. Potential subjects were identified from the new patient 
appointment records prior to their appointment dates. Referrals from other wards were traced on a daily basis by 
checking the referral records and liaising with the staff at the clinic reception and psychiatric medical officer on-call. 
A total of 98 patients were recruited over a twelve months period (from 1st May 2007 to 1st May 2008).  Inclusion 
criteria were i) All newly diagnosed patients with a Diagnostic and Statistical Manual of Mental Disorders Fourth 
Edition (DSM-IV) diagnosis of Major Depressive Disorder (MDD), Minor Depressive Disorder, Dysthymia or 
Adjustment Disorder (with depressed mood), ii) patients who were not on antidepressant or electroconvulsive therapy 
(ECT). Exclusion criteria included i) patients with psychotic illness other than Depressive Disorders, ii) patients 
with known thyroid disease, iii) patients who were already on treatment for a depressive illness. The study had been 
approved by the Medical Research and Ethics Committee, Faculty of Medicine, UKM. Both verbal and written 
consents were obtained on the enrolment day.
A maximum amount of 5 mls of venous blood was withdrawn from each subject. All serum assays were performed 
in the UKMMC Chemical Pathology laboratory. The blood samples were centrifuged and analyzed for TSH and FT4 
on the same day. Aliquots were stored at -20°C for the measurement of TPO-Ab, which was carried out in batches 
within one month after sample collection. 
Serum TSH concentrations were measured by a third-generation Architect TSH assay, using the Chemiluminescent 
Microparticle Immunoassay (CMIA) technology. In this study, the TSH reference range was taken as 0.45-4.5 mIU/L. 
Serum free T4 (FT4) with a reference range of 9.10-23.80 pmol/L was analyzed on Architect Free T4 assay, using the 
Chemiluminescent Microparticle Immunoassay (CMIA) technology. Serum anti-TPO with a normal range of less than 
5.61 IU/ml was analyzed on the AxSYM TPO-Ab assay, based on the Microparticle Enzyme Immunoassay (MEIA) 
technology.  Thyroid status was defined as in Table 1. 
Table 1. Biochemical definition of thyroid status*
* National Academy of Clinical Biochemistry (NACB) 200320
All clinical and laboratory data were stored and analyzed using the Statistical Package for Social Sciences (SPSS) 
statistical software version 18. The Kolmogorov-Smirnov test was used to assess normality of the distribution of the 
data. Results were expressed as mean values and standard deviation for normally distributed variables; whilst non-
parametric tests were used for analysis of variables that were not normally distributed and median values with 25 to 
75 percentiles were used. In all statistical analyses, p<0.05 (95% confidence interval) was considered significant. For 
categorical variables, measures of significance between groups were evaluated using the chi-square test. Pearson or 
Spearman correlation coefficients were calculated to estimate the linear correlation between continuous variables as 
Thyroid status TSH (mIU/ml) FT4 (pmol/L)
Euthyroid 0.4 – 4.50 9.10  – 23.80
Overt hypothyroid > 4.50 < 9.10
Subclinical hypothyroid > 4.50 9.10 – 23.80
Overt hyperthyroidism < 0.10 > 23.80
Subclinical hyperthyroid < 0.40 9.10 – 23.80
Discordant High or low TSH levels with inappropriate levels of FT4
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appropriately indicated. Similarly, either the t-test or Mann-Whitney U test was applied to test for differences between 
two independent groups on a continuous data.
RESULTS
The general characteristics of recruited patients are shown in Table 2. Thyroid status of the study population is shown 
in Table 3. Biochemically, majority of patients were euthyroid. Four patients (4%) were found to fit the diagnosis of 
subclinical hypothyroidism (none of whom had serum TSH levels more than 10.00 mIU/L). Eleven (11%) patients 
had subclinical hyperthyroidism. The correlation between serum TSH levels and age showed a non-significant weak 
negative correlation. There was a non-significant difference in the TSH levels of female and male patients.
Table 2. General characteristics and types of depressive disorders in patients with depression
Table 3. Thyroid status of patients with depression by gender
Twenty eight patients had comorbidities, three of whom had SHT. Table 4 shows the significant association between 
SHT and different types of comorbidities, namely hepatitis, liver cirrhosis and beta thalassaemia. In multivariate 
logistic regression analysis, the significant independent predictor of subclinical hypothyroidism was only hepatitis 
(Nagelkerke R2 = 0.375 and p = 0.015). However, cirrhosis and thalassaemia were not. 
Subtype Major 
Depressive 
Disorder
Minor 
Depressive 
Disorder
Adjustment 
Disorder
Dysthymia
(N= 98) (%) n (%) n (%) n (%) n (%)
Gender 
   Female
   Male
66
32
67
33
39
21             
59
65
3
0
5
0
16
7
24
22
8
4
12
13
Age
   <60 years
   ≥60 years
83
15
85
15
49
11
59
73
3
0
4
0
19
4
23
27
12
0
14
0
Thyroid status Female Male Both gender
(N= 66) (%) (N= 32) (%) (N= 98) (%)
Euthyroid 57 86 23 72 80 82
Overt hypothyroid 0 0 0 0 0 0
Subclinical hypothyroid 2 3 2 6 4 4
Overt hyperthyroid 1 1 0 0 1 1
Subclinical hyperthyroid 5 7 6 19 11 11
Discordant 1 1 1 3 2 2
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Table 4. Association between subclinical hypothyroidism and comorbidities in patients with depression
        * Significant at p< 0.05 
Table 5 shows TPO-Ab status of the study population. There was a weak positive correlation between anti-TPO titre 
and age, (r = 0.256 and p = 0.01). However, both the correlations between serum anti-TPO titre with TSH level and 
FT4 were weak and non-significant. In addition, there was no significant difference between anti-TPO titre of female 
and male patients and between the levels of anti-TPO titre in depressed patients with SHT and those without.
Table 5. Thyroid autoantibody status of patients with depression.
Comorbidities Χ2 with Yates correction P value 
Hepatitis 16.67 0.01*
Liver cirrhosis 5.44 0.02*
Thalassaemia 5.44 0.02*
Malignancies 0.00 1.00
End-stage renal failure 1.25 0.26
Type 2 Diabetes Mellitus (T2DM) 2.48 0.12
Hypertension 2.89 0.09
Acute renal failure 0.00 1.00
Adrenal failure 0.00 1.00
Rheumatoid arthritis 0.00 1.00
Opiod-dependency 0.00 1.00
Spondylolysis 0.00 1.00
Tuberculosis 0.00 1.00
Pulmonary embolism 0.00 1.00
Asthma 0.00 1.00
Peptic ulcer disease 0.76 0.38
Paraplegia 0.00 1.00
  TPO-Ab titer
Normal High 
(N= 91) (%) (N= 7) (%)
Euthyroid 74 82 6 86
Subclinical hypothyroidism 3 3 1 14
Overt hyperthyroidism 1 1 0 0
Subclinical hyperthyroidism 11 12 0 0
Discordant 2 2 0 0
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DISCUSSION
The prevalence of SHT in this study population was 4%.  Previous studies have indicated that it is probably higher in 
patients with refractory depression than in other types of depressed patients.19 In this study, the subjects were all non-
refractory cases comprised newly diagnosed, untreated patients. 
A diagnosis of SHT relies heavily on the definition of TSH upper reference limit (URL), taken at the 97.5th 
percentile of a population-based reference range.20 Recently, there has been much controversy regarding TSH upper 
reference limit. The arguments for and against has been widely discussed.1,4 Some authors conclude that the clinically 
relevant value is between 4 and 5 mIU/L.1 There has also been much growing interest in having age- and race-based 
reference range.1 In this study, the TSH reference range adopted was 0.45-4.5 mIU/L; whilst that of FT4 was 9.1-23.8 
pmol/L, as recommended by the experts4,20, in keeping with the most widely acceptable clinically relevant ranges.1
The time of sampling is also critical as the normal TSH diurnal rhythm, characterized by a peak around midnight 
and a decrease of up to 50% between 0800 to 0930 hours, may be displaced by sleep deprivation or exercise.20 It is 
recommended that TSH reference range be established from fasting morning samples of euthyroid subjects who, in 
addition to the above criteria, are also free of pathological thyroid ultrasonography findings.1,20 In this study, although 
patients were not necessarily fasted, the time of sampling occurred during working hours (between 0800 to 1700 
hour), as to minimize the effect of TSH diurnal rhythm.
Inter-assay variability of TSH must also be borne in mind, both within the current third generation and across 
the different generations. Thus, the differences in the prevalence of SHT observed in various studies not only reflect 
differences in population studied,  but also in TSH reference range used, as well as TSH and TPO-Ab assays.
Transient TSH elevation may also occur during the recovery phase of euthyroid sick syndrome (non-thyroidal 
illness), chronic kidney disease (CKD) or untreated adrenal failure.1 In hospitalized patients, transient abnormalities 
up to 20.0 mIU/L range may be seen during recovery from non-thyroidal illness.21 Strictly speaking, SHT cannot be 
easily diagnosed during a hospitalization due to this phenomenon. However, concurrent measurement of TPO-Ab titer 
would differentiate autoimmune thyroid disease from non-thyroidal illness.20
Presence of CKD may explain elevated TSH in 2 out of 4 patients with SHT in this study. Chonchol et al22 has 
shown that SHT was a relatively common condition (18%) among persons with CKD, not requiring chronic dialysis. 
However, in this study, patients with end-stage renal failure (ESRF) were all dialysis-dependent and there was no 
significant association between ESRF and SHT. Patients with untreated adrenal insufficiency may have high, often 
reversible, serum TSH.23 In this study, there was one patient with adrenal failure, whose euthyroid state may be 
explained by him being on treatment. 
Three out of 4 patients with SHT had comorbidities and their TPO-Ab titres were within normal range. Thus, 
their mildly elevated TSH (<10 mIU/L) may actually be transient, presumably occurring during recovery phase of 
their acute illnesses. Ideally, evaluation of thyroid function should be deferred until 2-3 months after discharge. Three 
medical illnesses, namely hepatitis, liver cirrhosis and thalassaemia showed significant association with SHT. On 
further statistical analysis, however, only hepatitis was shown to independently affect the probability of having SHT. 
Although statistical analysis showed that hepatitis contributed 37.5% (Nagelkerke R2 = 0.375) of the variation in the 
occurrence of SHT, it should be interpreted with caution due to the small sample size and convenient sampling method. 
A recent study showed that a spectrum of thyroid dysfunction existed in untreated chronic hepatitis C patients, 
and that SHT was the most prevalent type.24 The underlying pathogenesis of thyroid dysfunction in these untreated 
patients was likely to be associated with autoimmunity.24 Another recent study has also shown that thyroid dysfunction 
developed in 10% of patients treated with interferon-α, with hypothyroidism being the most common presentation.25 
It is currently suggested that interferon induces thyroid dysfunction by both autoimmune and non-autoimmune 
mechanisms.26  In this study, two of SHT patients had chronic hepatitis, (the subtype of which was not ascertained), 
and none was on interferon treatment.
SHT is a common finding in type 1 diabetes mellitus (T1DM)27 and probably other autoimmune diseases. A 
recent study has found significant prevalence of either SHT (6.3%) or overall thyroid dysfunction (32.4%) in T2DM.28 
In this study, 2 patients with SHT had T2DM. However, statistical analysis showed no significant association between 
T2DM or autoimmune diseases, such as rheumatoid arthritis, with SHT. 
Incidentally, there was a relatively high prevalence of subclinical hyperthyroidism among the subjects, found 
in 11 patients (11%), 4 of whom had other medical illnesses.  In the latter group of patients, as their TSH levels 
varied between 0.03-0.33 mIU/L, their TSH levels may be explained by transient mild TSH suppression commonly 
seen in non-thyroidal illness.20 Nevertheless, although subclinical hyperthyroidism is less prevalent than subclinical 
hypothyroidism, and is less commonly associated with depression2, this finding may reflect that subclinical thyroid 
disorders, in combination, are prevalent among patients with depressive disorders. 
TPO-Ab is involved in the thyroid hormone synthesis. Pathologically, it is implicated in the tissue destructive 
process in Hashimoto’s thyroiditis. Thus, TPO-Ab is the most sensitive test for detecting autoimmune thyroid disease 
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(AITD) and its detectable titre typically precedes TSH elevation, making it the first biochemical abnormality detected 
in the disease course.20 Varying degrees of clinical and subclinical hypothyroidism as well as positive TPO-Ab titres, 
suggestive of asymptomatic autoimmune thyroiditis, have been observed in depressed patients.9,10,19,29
Several studies have shown 8% to 20% prevalence of anti-thyroid antibody positivity among depressed patients, 
supporting the hypothesis of subtle thyroid dysfunction in these patients. However, these findings must be interpreted 
with caution.8
In this study, the prevalence of anti-thyroid antibody positivity was 7%, which was comparable to figures found 
by the previous studies and not significantly different from the rate in the general population. One patient with positive 
TPO-Ab titre had SHT, which in this case may be due to symptomless autoimmune thyroiditis. Upon confirmation of 
the diagnosis of SHT, one may proceed with an ultrasonic examination of the thyroid gland. The risk of her developing 
an overt hypothyroidism was favoured by her female gender and positive TPO-Ab. However, young age and mild 
degree of TSH elevation may favour normalization.  Six patients with positive TPO-Ab titer were biochemically 
euthyroid and were all female, including 3 elderly (≥60 years). These patients might have symptomless Hashimoto’s 
thyroiditis and therefore were at risk of developing thyroid failure.  They should be followed up, as suggested above. 
The prevalence of thyroid autoantibodies increases in patients with non-thyroid autoimmune diseases, such as 
rheumatoid arthritis and T1DM.30,31 Among patients with positive TPO-Ab titre, two had concurrent spondylolysis, 
which is a degenerative non-immune condition. Their positive TPO-Ab titre, therefore, could not be explained by 
presence of non-thyroidal autoimmune disease. However, being an elderly (≥60 years) female is a known risk factor 
for positive TPO-Ab. 
With limitation such as short duration and small sample size, the findings were strong enough to propose a 
more extensive study with a bigger sample size. A repeat testing of serum TSH and FT4 at 2-12 weeks is strongly 
recommended to confirm the diagnosis of SHT, as well as to see the progress of the illness. It would also be interesting 
to assess the association between severity of depression and thyroid dysfunction.
CONCLUSION
The prevalence of SHT among patients with newly-diagnosed depressive disorders was 4%. Incidentally, the 
prevalence of subclinical hyperthyroidism was 11%. Hepatitis showed a significant association with SHT; whilst other 
comorbidities did not. TPO-Ab titer was positive in 7% of the study population, one of whom had SHT. However, 
TPO-Ab positivity was more prevalent in young female subjects, in contrast to that found in the general population. 
Although the prevalence of SHT alone was low, in combination, the prevalence of subclinical thyroid disorders in 
this study was 15%. This may support routine thyroid function test all newly diagnosed depressed patients. TPO-Ab 
testing would be complementary in identifying possible cases of asymptomatic thyroiditis.
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